The prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned development of RG6206, a myostatin inhibitor. The Swiss group revealed the ...

Peptidream Inc. has released promising results from preclinical testing of its oral myostatin inhibitors, administered in combination with semaglutide, in a mouse model of obesity. Peptidream’s oral ...

Scholar Rock will be initiating a Phase II trial of its spinal muscular atrophy pipeline drug apitegromab alongside a GLP-1 receptor agonist (GLP-1ra) in patients with obesity months after being ...